Rockwell Medical (Rockwell Medical) GF Score : 57/100 (As of Jun. 06, 2024)

View and export this data going back to 1998. Start your Free Trial

What is Rockwell Medical GF Score?

Rockwell Medical has the GF Score of 57, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 1/10
3. Growth Rank : 3/10
4. GF Value Rank : 5/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Rockwell Medical might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Rockwell Medical's GF Score

For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rockwell Medical's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's GF Score distribution charts can be found below:

* The bar in red indicates where Rockwell Medical's GF Score falls into.

Rockwell Medical (NAS:RMTI) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Rockwell Medical GF Score Related Terms

Thank you for viewing the detailed overview of Rockwell Medical's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Rockwell Medical (Rockwell Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rockwell Medical Inc (NAS:RMTI) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

RWMA:Germany

Address

30142 S. Wixom Road, Wixom, MI, USA, 48393

Website

https://www.rockwellmed.com

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. Rockwell Medical's mission is to provide dialysis clinics and patients with the highest quality products supported by the best customer service in the industry. It is focused on innovative, long-term growth strategies that enhance products, processes, and people, enabling the company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients.

Executives

Jesse Neri	officer: SVP, FINANCE	851 DUPORTAIL ROAD, SECOND FLOOR, CHESTERBROOK PA 19087
Joan Lau	director	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Russell Skibsted	officer: See Remarks	15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Megan C. Timmins	officer: SVP, General Counsel	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Mark Strobeck	director, officer: President and CEO	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Allen Nissenson	director	601 HAWAII ST., EL SEGUNDO CA 90245
Robert S Radie	director	101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Andrea Heslin Smiley	director	600 LEE ROAD, SUITE 100, WAYNE PA 19087
David S. Richmond	10 percent owner, other: See Footnote 1	3568 WILDWOOD AVENUE, JACKSON MI 49202
Russell H Ellison	director	270 RIVERSIDE DR., APT. 12D, NEW YORK NY 10025
Marc L Hoffman	officer: Chief Medical Officer	30142 WIXOM ROAD, WIXOM MI 48393
John Peter Mclaughlin	director	C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Richmond Brothers, Inc.	10 percent owner, other: See Footnote 1	7415 FOXWORTH COURT, JACKSON MI 49201
Stuart M Paul	director, officer: Chief Executive Officer	HOME DIAGNOSTICS, INC., 2400 NW 55TH COURT, FORT LAUDERDALE FL 33309
Angus W. Smith	officer: Chief Financial Officer	C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960